Premium
Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy
Author(s) -
Allaqaband Suhail,
Tumuluri Ramagopal,
Malik Ahmed M.,
Gupta Anjan,
Volkert Paul,
Shalev Yoseph,
Bajwa Tanvir K.
Publication year - 2002
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10323
Subject(s) - medicine , fenoldopam , acetylcysteine , saline , nephropathy , prospective cohort study , randomized controlled trial , urology , anesthesia , endocrinology , agonist , receptor , diabetes mellitus , biochemistry , chemistry , antioxidant
The objective of this study was to compare the efficacy of N‐acetylcysteine (NAC), fenoldopam, and saline in preventing radiocontrast‐induced nephropathy (RCIN) in high‐risk patients undergoing cardiovascular procedures. We prospectively enrolled 123 patients who were scheduled for cardiovascular procedures and had a baseline creatinine > 1.6 mg/dl or creatinine clearance of < 60 ml/min. Patients were randomly assigned to receive either saline (0.45% normal saline at 1 cc/kg) for 12 hr before and 12 hr after the procedure, or fenoldopam (0.1 μg/kg/min) plus saline for 4 hr prior and 4 hr after the procedure, or NAC orally (600 mg) plus saline every 12 hr for 24 hr prior and 24 hr after the procedure. All the patients received low‐osmolality nonionic contrast. RCIN was defined as an increase in creatinine level > 0.5 mg/dl after 48 hr. The incidence of RCIN was 17.7% in the NAC group, 15.3% in the saline group, and 15.7% in the fenoldopam group ( P = 0.919). Of the 20 patients who developed RCIN, 2 required dialysis. Serum creatinine decreased after 48 hr (vs. baseline) in 38% patients in the NAC group, 18% in the fenoldopam group, and 15% in the saline group. In patients with chronic renal insufficiency, NAC or fenoldopam offered no additional benefit over hydration with saline in preventing RCIN. Cathet Cardiovasc Intervent 2002;57:279–283. © 2002 Wiley‐Liss, Inc.